What Is The Ceed Medical Cannabis Brand?

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), announced today that it is the first company to formulate medical cannabis extract vaporizer pen products in a UK-based manufacturing premises, licensed and approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Home Office.

The products launched under its flagship medical Ceed brand and are comprised of four formulations that will be available for patients throughout the UK when prescribed by a specialist consultant. These new vaporizer pens complete Columbia Care’s initial medical product portfolio, which includes tinctures, launched in April 2020, and its proprietary solid-fill powder capsules, launched in April 2021, that remain unique in the UK market. This portfolio of products offers clinicians and patients in the UK the broadest range of medicinal cannabis products with the capability to target different onset periods and duration of effect.

“Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available. There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients. We are proud to leverage our proprietary IP, formulation expertise, safety surveillance and patient reported data from the U.S. to bring innovation and precision to the growing UK medical cannabis market. We are witnessing increasing numbers of leading doctors integrate the use of medicinal cannabis into their practice evidencing growing acceptance in the UK of the clinical value of cannabinoids,” said Nicholas Vita, CEO, Columbia Care.

The four new Ceed vaporizer formulations have been selected based on insights from Columbia Care’s IMPACT Registry^TM and from feedback provided by UK-based patients. The range offers two different THC:CBD ratios, each with two different terpene profile options — either uplifting or calming. The cartridges are formulated in the UK in MHRA and Home Office approved facilities, using Columbia Care’s formulation methodology developed from its years of experience in the U.S. Vaporizers offer patients a discrete and easy-to-use method which U.S.-based patients have included in their daily lives. When compared with flower, often used for its fast-acting effects, it particularly appeals to cannabis-naïve patients and those with limited dexterity or motor function.

With the addition of these vaporizers, the Ceed product line now offers three different pharmacokinetic options for clinicians to use in their practice. Vaporizers offer a fast onset option, which the IMPACT Registry^TM demonstrates is commonly used by patients alongside another formulation such as a tincture or capsule. Those formulations provide longer-lasting effects for patients throughout the course of the day or for patients seeking night-long effects while they sleep.

“UK clinicians practising with cannabis have been telling us that they find cannabis flower difficult to dose, but they recognise the need for fast-onset options for patients experiencing breakthrough pain. With the introduction of these vaporizer cartridges, clinicians now have a toolkit of doseable formulations with a range of onset period and duration to help their patients in a similar way to how they use other medicines. The vaporizers also have the advantage of being discrete and easy to use which will help many patients who are either cannabis-naïve or who want to continue with their regular daily activities, such as going to work, without the fear of being judged. We are delighted to be able to bring this important line of products to the UK market,” said Rosemary Mazanet, M.D./Ph.D., Chief Scientific Officer, Columbia Care.

IPS Pharma will dispense Columbia Care vaporizers and cartridges directly to patients nationwide. It is also expected that these will be available across a wider range of the pharmacies dispensing medicinal cannabis prescriptions in the coming weeks.

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 18 U.S. jurisdictions and the EU. Columbia Care operates 131 facilities including 99 dispensaries and 32 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.col-care.com.

About Columbia Care International

Columbia Care International is part of Columbia Care and is currently focused on serving the medical cannabis markets in the UK and Germany and the UK hemp-derived wellness market. It is responsible for developing industry-leading, specialist medicinal formulations through its Ceed line and supplies hemp-derived wellness brand Columbia Care Platinum to consumers in the UK. Columbia Care International works with healthcare professionals, regulators, patient groups and those with an interest in improving healthcare outcomes to bring these cannabis products to the market. In early 2021, the Company was the first to launch a solid-fill medical cannabis capsule in the UK. For more information on Columbia Care International, please visit www.columbia-care.com.

Caution Concerning Forward-Looking Statements

This press release contains certain statements that constitute forward-looking information within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. The Company has made assumptions with regard to its ability to execute on brand and product initiatives, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. Securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Annual Information Form dated March 31, 2021, filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and described from time to time in documents filed by the Company with Canadian securities regulatory authorities.